BioSpace News Archive

AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases, announced the completion of enrollment into the DISCOVER trial.

Arch Therapeutics, Inc. announced that the Company’s first commercial product, AC5® Advanced Wound System, will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting, which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.

Apellis Pharmaceuticals, Inc. announced that the company will host a fireside chat at the Bank of America Securities Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. PT.

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced financial results for the first quarter of 2024.

Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open.

BioCryst Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Scientia Vascular, a leader in neurovascular innovation, is thrilled to announce the FDA clearance of two uniquely engineered catheters: the Plato 17—a DMSO-compatible microcatheter—and the Socrates 38, an aspiration catheter engineered for ischemic stroke.

BioLineRx Ltd. announced that new economic model data will be presented on APHEXDA® for CD34+ hematopoietic stem cell mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research – The Professional Society for Health Economics and Outcomes Research – 2024 conference, taking place May 5-8, 2024, in Atlanta, Georgia.

Mediar Therapeutics, Inc. announced that, following FDA clearance of its investigational new drug application, the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-463.

Ginkgo Bioworks announced its participation in the 27th American Society of Gene & Cell Therapy Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.